Oncology Position

shut up bitch

 

Testify

 

Told you so, 29%ORR in NSCLC, PD1 ORRs are typically in the teens. BAM!

 

did we get approval in lung??

 

No approval in lung, that dumbass is wetting themselves over response rate data in a phase I trial. There's a long arduous road ahead for a lung cancer approval. Hell, not even approved in cscc yet. In today's oncology market, approval is no guarantee of commercial success either. Good luck, it's going to take a lot of it on this one.

 

True dat. The pool is calling.

 

You got all summer long. Enjoy!

 

Great to see the stock close below $300/shr again today. Investors very confident.

 

Keytruda killed it at ASCO, by the time REGN PD1-I is approved, it will already be game over.

 

Keytruda is a beast. Seems like more indications every month and new data all the time. It's gonna be damn near impossible to launch another PD1 inhibitor.

 

summertime.....and the livin’ is easy!

 

Can't wait for that sweet launch. By then we'll be what....7th to market?

 

(Yawn) what time is it.....is it Thursday?

 

You guys are dimwits.

Immuno-oncology is projected to be a $30 billion market and Merck bet the farm on Keytruda taking the lionshare of it.

Regeneron is a small company. You don’t need a PD1 homerun. What would 1% of $30B do for your bottom line. $300M per year? Not bad. Go for more but not bad.

You need to be in it but you don’t have to win it.

 

And you don't understand the obstacles to market entry at this point. They will be lucky to sell $15M the first 12 months.

 

What do you do all day waiting for the approval???

How many meetings and prep can you do?

 

Seriously when is this thing getting approved? I am running out of vacation ideas and money to travel.

 

Competition will already have your business when the drug is approved. Stay on vacation.

 

have all these jobs been filled or are there still openings?

 

Yes, these are all filled but they will be hiring more in 2019, as new indications are gained they will start to staff up with more field staff so stay tuned